These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36729854)

  • 1. The Potential Pathogenicity of Myelin Oligodendrocyte Glycoprotein Antibodies in the Optic Pathway.
    Lerch M; Bauer A; Reindl M
    J Neuroophthalmol; 2023 Mar; 43(1):5-16. PubMed ID: 36729854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review.
    Tanaka K; Kezuka T; Ishikawa H; Tanaka M; Sakimura K; Abe M; Kawamura M
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
    Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
    J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
    Jarius S; Pellkofer H; Siebert N; Korporal-Kuhnke M; Hümmert MW; Ringelstein M; Rommer PS; Ayzenberg I; Ruprecht K; Klotz L; Asgari N; Zrzavy T; Höftberger R; Tobia R; Buttmann M; Fechner K; Schanda K; Weber M; Asseyer S; Haas J; Lechner C; Kleiter I; Aktas O; Trebst C; Rostasy K; Reindl M; Kümpfel T; Paul F; Wildemann B;
    J Neuroinflammation; 2020 Sep; 17(1):261. PubMed ID: 32883348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
    Banwell B; Bennett JL; Marignier R; Kim HJ; Brilot F; Flanagan EP; Ramanathan S; Waters P; Tenembaum S; Graves JS; Chitnis T; Brandt AU; Hemingway C; Neuteboom R; Pandit L; Reindl M; Saiz A; Sato DK; Rostasy K; Paul F; Pittock SJ; Fujihara K; Palace J
    Lancet Neurol; 2023 Mar; 22(3):268-282. PubMed ID: 36706773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies.
    Lee HJ; Kim B; Waters P; Woodhall M; Irani S; Ahn S; Kim SJ; Kim SM
    J Neuroinflammation; 2018 Oct; 15(1):302. PubMed ID: 30382857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
    Burton JM; Youn S; Al-Ani A; Costello F
    J Neurol; 2024 May; 271(5):2662-2671. PubMed ID: 38366070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelin oligodendrocyte glycoprotein-IgG-associated optic neuritis.
    Chun BY; Cestari DM
    Curr Opin Ophthalmol; 2018 Nov; 29(6):508-513. PubMed ID: 30281030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial.
    Chen JJ; Tobin WO; Majed M; Jitprapaikulsan J; Fryer JP; Leavitt JA; Flanagan EP; McKeon A; Pittock SJ
    JAMA Ophthalmol; 2018 Apr; 136(4):419-422. PubMed ID: 29470571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG-Associated Experimental Autoimmune Encephalomyelitis.
    Remlinger J; Madarasz A; Guse K; Hoepner R; Bagnoud M; Meli I; Feil M; Abegg M; Linington C; Shock A; Boroojerdi B; Kiessling P; Smith B; Enzmann V; Chan A; Salmen A
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35027475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk factors for recurrence of myelin oligodendrocyte glycoprotein antibody-associated disease.
    Wang J; Yang K; Zhang F; Yi Y; Wang J
    Mult Scler Relat Disord; 2023 Sep; 77():104879. PubMed ID: 37442076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis.
    Jitprapaikulsan J; Chen JJ; Flanagan EP; Tobin WO; Fryer JP; Weinshenker BG; McKeon A; Lennon VA; Leavitt JA; Tillema JM; Lucchinetti C; Keegan BM; Kantarci O; Khanna C; Jenkins SM; Spears GM; Sagan J; Pittock SJ
    Ophthalmology; 2018 Oct; 125(10):1628-1637. PubMed ID: 29716788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual outcome measures in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
    Gericke FC; Hanson JVM; Hackenberg A; Gerth-Kahlert C
    Eur J Paediatr Neurol; 2024 Jan; 48():113-120. PubMed ID: 38217965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.
    Matsumoto Y; Park IK; Hiraki K; Ohtani S; Kohyama K
    Immunology; 2009 Sep; 128(1 Suppl):e250-61. PubMed ID: 19175799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applicability of the New Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease Diagnostic Criteria in an Israeli Cohort.
    Fineberg A; Lotan I; Bialer O; Tiosano A; Rozenblatt S; Wilf-Yarkoni A; Hellmann MA; Stiebel-Kalish H
    Isr Med Assoc J; 2024 Aug; 26(7):434-440. PubMed ID: 39082453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome.
    Wendel EM; Thonke HS; Bertolini A; Baumann M; Blaschek A; Merkenschlager A; Karenfort M; Kornek B; Lechner C; Pohl D; Pritsch M; Schanda K; Schimmel M; Thiels C; Waltz S; Wiegand G; Anlar B; Barisic N; Blank C; Breu M; Broser P; Della Marina A; Diepold K; Eckenweiler M; Eisenkölbl A; Freilinger M; Gruber-Sedlmayr U; Hackenberg A; Iff T; Knierim E; Koch J; Kutschke G; Leiz S; Lischetzki G; Nosadini M; Pschibul A; Reiter-Fink E; Rohrbach D; Salandin M; Sartori S; Schlump JU; Stoffels J; Strautmanis J; Tibussek D; Tüngler V; Utzig N; Reindl M; Rostásy K;
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36229191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.